{"id":6232,"date":"2023-01-03T09:44:22","date_gmt":"2023-01-03T08:44:22","guid":{"rendered":"https:\/\/www.rapharm.eu\/hr\/?p=6232"},"modified":"2023-01-03T09:45:20","modified_gmt":"2023-01-03T08:45:20","slug":"eu-novo-ogranicenje-sastojaka-u-dodacima-prehrani","status":"publish","type":"post","link":"https:\/\/www.rapharm.eu\/hr\/eu-novo-ogranicenje-sastojaka-u-dodacima-prehrani\/","title":{"rendered":"EU: Novo ograni\u010denje sastojaka u dodacima prehrani"},"content":{"rendered":"<style type=\"text\/css\"><\/style>\n<p>U vezi s\n\u010dlankom 8. stavkom 2. Uredbe (EZ) br. 1925\/2006, Komisija je donijela Uredbu\nbr. 2022\/2340, koja ograni\u010dava upotrebu EGCG-a, odnosno\n(-)-epigalokatehin-3-galata u ekstraktima zelenog \u010daja, jer predstavlja potencijalni\nrizik za potro\u0161a\u010de, koji u dnevnim dozama ve\u0107im od 800 mg mo\u017ee uzrokovati\nstatisti\u010dki zna\u010dajno pove\u0107anje serumskih transaminaza kod osoba\nkoje su primale te doze u usporedbi s kontrolnim ispitanicima, \u0161to upu\u0107uje na\no\u0161te\u0107enje jetre. <\/p>\n\n\n\n<p>Zeleni \u010daj se\nproizvodi od li\u0161\u0107a Camellia sinensis (L.) Kuntze bez fermentacije, koja\nuklju\u010duje prisutnost flavanola, poznatih kao katehini, od kojih je najva\u017eniji\n(-)-epigalokatehin-3-galat. Katehini iz zelenog \u010daja mogu se konzumirati u\nobliku tradicionalnih infuza zelenog \u010daja, instant napitaka od \u010daja ili dodatka\nprehrani koji sadr\u017eava koncentrirane ekstrakte zelenog \u010daja s vrlo razli\u010ditim\nrazinama (-)-epigalokatehin-3-galata.<\/p>\n\n\n\n<p>EGCG je stoga\nograni\u010den na 800 mg dnevno, na ambala\u017ei moraju biti navedena sljede\u0107a upozorenja.<\/p>\n\n\n\n<p><strong>Trebate li dodatno znanje ili pomo\u0107 u provjeri sukladnosti sastojaka i\ndrugih svojstava proizvoda prije ulaska na tr\u017ei\u0161te?<\/strong><\/p>\n\n\n\n<p>Uz pomo\u0107\nna\u0161ih <a href=\"https:\/\/www.rapharm.eu\/hr\/savjetovanje-i-usluge\/\">savjetovanja<\/a> u potpunosti\nVam mo\u017eemo pomo\u0107i u temeljitim pregledima sukladnosti proizvoda za ulazak na\nva\u0161e tr\u017ei\u0161te, kao i na inozemna tr\u017ei\u0161ta te mogu\u0107nosti legalnog marketinga dodataka\nprehrani.<\/p>\n\n\n\n<p>Vir: <\/p>\n\n\n\n<p><a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/HR\/TXT\/PDF\/?uri=CELEX:32022R2340&amp;qid=1671520149088&amp;from=en\">Publications\nOffice (europa.eu)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>U vezi s \u010dlankom 8. stavkom 2. Uredbe (EZ) br. 1925\/2006, Komisija je donijela Uredbu br. 2022\/2340, koja ograni\u010dava upotrebu EGCG-a, odnosno (-)-epigalokatehin-3-galata u ekstraktima zelenog \u010daja, jer predstavlja potencijalni rizik za potro\u0161a\u010de, koji u dnevnim dozama ve\u0107im od 800 mg mo\u017ee uzrokovati statisti\u010dki zna\u010dajno pove\u0107anje serumskih transaminaza kod osoba koje su primale te doze&#8230;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[46],"tags":[],"class_list":["post-6232","post","type-post","status-publish","format-standard","hentry","category-novice-hr"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EU: Novo ograni\u010denje sastojaka u dodacima prehrani - raPHARM<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/\" \/>\n<meta property=\"og:locale\" content=\"hr_HR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EU: Novo ograni\u010denje sastojaka u dodacima prehrani - raPHARM\" \/>\n<meta property=\"og:description\" content=\"U vezi s \u010dlankom 8. stavkom 2. Uredbe (EZ) br. 1925\/2006, Komisija je donijela Uredbu br. 2022\/2340, koja ograni\u010dava upotrebu EGCG-a, odnosno (-)-epigalokatehin-3-galata u ekstraktima zelenog \u010daja, jer predstavlja potencijalni rizik za potro\u0161a\u010de, koji u dnevnim dozama ve\u0107im od 800 mg mo\u017ee uzrokovati statisti\u010dki zna\u010dajno pove\u0107anje serumskih transaminaza kod osoba koje su primale te doze...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/\" \/>\n<meta property=\"og:site_name\" content=\"raPHARM\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-03T08:44:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-03T08:45:20+00:00\" \/>\n<meta name=\"author\" content=\"rapharm\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rapharm\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/\",\"url\":\"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/\",\"name\":\"EU: Novo ograni\u010denje sastojaka u dodacima prehrani - raPHARM\",\"isPartOf\":{\"@id\":\"https:\/\/www.rapharm.eu\/#website\"},\"datePublished\":\"2023-01-03T08:44:22+00:00\",\"dateModified\":\"2023-01-03T08:45:20+00:00\",\"author\":{\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/#breadcrumb\"},\"inLanguage\":\"hr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.rapharm.eu\/hr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU: Novo ograni\u010denje sastojaka u dodacima prehrani\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rapharm.eu\/#website\",\"url\":\"https:\/\/www.rapharm.eu\/\",\"name\":\"raPHARM\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rapharm.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"hr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1\",\"name\":\"rapharm\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g\",\"caption\":\"rapharm\"},\"url\":\"https:\/\/www.rapharm.eu\/hr\/author\/rapharm\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EU: Novo ograni\u010denje sastojaka u dodacima prehrani - raPHARM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/","og_locale":"hr_HR","og_type":"article","og_title":"EU: Novo ograni\u010denje sastojaka u dodacima prehrani - raPHARM","og_description":"U vezi s \u010dlankom 8. stavkom 2. Uredbe (EZ) br. 1925\/2006, Komisija je donijela Uredbu br. 2022\/2340, koja ograni\u010dava upotrebu EGCG-a, odnosno (-)-epigalokatehin-3-galata u ekstraktima zelenog \u010daja, jer predstavlja potencijalni rizik za potro\u0161a\u010de, koji u dnevnim dozama ve\u0107im od 800 mg mo\u017ee uzrokovati statisti\u010dki zna\u010dajno pove\u0107anje serumskih transaminaza kod osoba koje su primale te doze...","og_url":"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/","og_site_name":"raPHARM","article_published_time":"2023-01-03T08:44:22+00:00","article_modified_time":"2023-01-03T08:45:20+00:00","author":"rapharm","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rapharm","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/","url":"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/","name":"EU: Novo ograni\u010denje sastojaka u dodacima prehrani - raPHARM","isPartOf":{"@id":"https:\/\/www.rapharm.eu\/#website"},"datePublished":"2023-01-03T08:44:22+00:00","dateModified":"2023-01-03T08:45:20+00:00","author":{"@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1"},"breadcrumb":{"@id":"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/#breadcrumb"},"inLanguage":"hr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rapharm.eu\/eu-nova-omejitev-sestavin-v-prehranskih-dopolnilih\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rapharm.eu\/hr\/"},{"@type":"ListItem","position":2,"name":"EU: Novo ograni\u010denje sastojaka u dodacima prehrani"}]},{"@type":"WebSite","@id":"https:\/\/www.rapharm.eu\/#website","url":"https:\/\/www.rapharm.eu\/","name":"raPHARM","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rapharm.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"hr"},{"@type":"Person","@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1","name":"rapharm","image":{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g","caption":"rapharm"},"url":"https:\/\/www.rapharm.eu\/hr\/author\/rapharm\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/posts\/6232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/comments?post=6232"}],"version-history":[{"count":1,"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/posts\/6232\/revisions"}],"predecessor-version":[{"id":6233,"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/posts\/6232\/revisions\/6233"}],"wp:attachment":[{"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/media?parent=6232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/categories?post=6232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rapharm.eu\/hr\/wp-json\/wp\/v2\/tags?post=6232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}